SG11202008098TA - Antibody-based methods of detecting and treating alzheimer's disease - Google Patents
Antibody-based methods of detecting and treating alzheimer's diseaseInfo
- Publication number
- SG11202008098TA SG11202008098TA SG11202008098TA SG11202008098TA SG11202008098TA SG 11202008098T A SG11202008098T A SG 11202008098TA SG 11202008098T A SG11202008098T A SG 11202008098TA SG 11202008098T A SG11202008098T A SG 11202008098TA SG 11202008098T A SG11202008098T A SG 11202008098TA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- disease
- detecting
- based methods
- treating alzheimer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649208P | 2018-03-28 | 2018-03-28 | |
| US201862664662P | 2018-04-30 | 2018-04-30 | |
| US201862703299P | 2018-07-25 | 2018-07-25 | |
| PCT/IB2019/000358 WO2019186276A2 (en) | 2018-03-28 | 2019-03-27 | Antibody-based methods of detecting and treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202008098TA true SG11202008098TA (en) | 2020-10-29 |
Family
ID=66999856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202008098TA SG11202008098TA (en) | 2018-03-28 | 2019-03-27 | Antibody-based methods of detecting and treating alzheimer's disease |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3774887A2 (ru) |
| JP (1) | JP2021520777A (ru) |
| KR (1) | KR20200144551A (ru) |
| CN (1) | CN112236452A (ru) |
| AU (1) | AU2019244481A1 (ru) |
| BR (1) | BR112020018868A2 (ru) |
| CA (1) | CA3095443A1 (ru) |
| IL (1) | IL277577A (ru) |
| MX (1) | MX2020009991A (ru) |
| RU (1) | RU2020135052A (ru) |
| SG (1) | SG11202008098TA (ru) |
| WO (1) | WO2019186276A2 (ru) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2970453B1 (en) | 2013-03-13 | 2019-12-04 | Prothena Biosciences Limited | Tau immunotherapy |
| WO2017191559A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Tau immunotherapy |
| UA124148C2 (uk) | 2016-05-02 | 2021-07-28 | Протена Біосайенсіс Лімітед | Антитіла, що розпізнають тау |
| BR112019022906A2 (pt) | 2017-05-02 | 2020-05-26 | Prothena Biosciences Limited | Anticorpos que reconhecem tau |
| SG11202108414UA (en) | 2019-03-03 | 2021-08-30 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| JP2022547513A (ja) | 2019-09-09 | 2022-11-14 | アクソン ニューロサイエンス エスエー | アルツハイマー病及び軽度認知障害のバイオマーカー及び治療 |
| JP2023554382A (ja) * | 2020-12-16 | 2023-12-27 | ボイジャー セラピューティクス インコーポレイテッド | タウ結合化合物 |
| CA3203800A1 (en) * | 2021-02-19 | 2022-08-25 | Eisai R&D Management Co., Ltd. | Anti-pt217 tau antibody |
| CN117003863A (zh) * | 2022-04-28 | 2023-11-07 | 厦门大学 | 针对p-tau 217的抗体及其用途 |
| CN114778856B (zh) * | 2022-05-30 | 2023-03-17 | 苏州宇测生物科技有限公司 | 磷酸化tau蛋白检测试剂盒 |
| WO2024040212A2 (en) * | 2022-08-19 | 2024-02-22 | Staidson Biopharma Inc. | Antibodies specifically recognizing programmed cell death 1 ligand 1 and uses thereof |
| CN117624351A (zh) * | 2023-11-24 | 2024-03-01 | 无锡傲锐东源生物科技有限公司 | 一种抗人磷酸化tau181兔单克隆抗体及其应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| FI102355B (fi) | 1988-02-11 | 1998-11-30 | Squibb Bristol Myers Co | Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjug aattien valmistamiseksi |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| AU677216B2 (en) | 1992-07-27 | 1997-04-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Targeting of liposomes to the blood-brain barrier |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| CN1151842C (zh) | 1995-07-27 | 2004-06-02 | 基因技术股份有限公司 | 稳定等渗的冻干蛋白制剂 |
| DK0871490T3 (da) | 1995-12-22 | 2003-07-07 | Bristol Myers Squibb Co | Forgrenede hydrazonlinkere |
| WO1998022120A1 (en) * | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| DK1521831T3 (da) | 2002-07-12 | 2008-06-30 | Axon Neuroscience | Transgent dyr der udtrykker trunkeret alzheimers tauprotein |
| CA2791165C (en) | 2002-12-03 | 2015-02-24 | Blanchette Rockefeller Neurosciences Institute | A conjugate comprising cholesterol linked to tetracycline |
| BR0317747A (pt) | 2002-12-24 | 2005-11-22 | Neurochem Int Ltd | Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave |
| SG10201701737XA (en) | 2003-11-06 | 2017-04-27 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| WO2008140639A2 (en) * | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
| US8093018B2 (en) * | 2008-05-20 | 2012-01-10 | Otsuka Pharmaceutical Co., Ltd. | Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same |
| US8613924B2 (en) * | 2009-08-06 | 2013-12-24 | Immunas Pharma, Inc. | Antibodies that specifically bind to A beta oligomers and use thereof |
| UA115657C2 (uk) * | 2011-09-19 | 2017-12-11 | Аксон Ньюросайєнс Сє | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла |
| MY178142A (en) * | 2011-12-20 | 2020-10-05 | Janssen Biotech Inc | Anti-phf-tau antibodies and their uses |
| US8853505B2 (en) * | 2012-02-27 | 2014-10-07 | Syngenta Participations Ag | Variety corn line AA2205 |
| US8980270B2 (en) * | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| RS61431B1 (sr) * | 2014-11-19 | 2021-03-31 | Axon Neuroscience Se | Humanizovana antitela na tau u alchajmerovoj bolesti |
| WO2017133673A1 (zh) * | 2016-02-05 | 2017-08-10 | 江苏恒瑞医药股份有限公司 | 凝血酶抗体、其抗原结合片段及医药用途 |
-
2019
- 2019-03-27 BR BR112020018868-9A patent/BR112020018868A2/pt unknown
- 2019-03-27 SG SG11202008098TA patent/SG11202008098TA/en unknown
- 2019-03-27 EP EP19732436.1A patent/EP3774887A2/en active Pending
- 2019-03-27 RU RU2020135052A patent/RU2020135052A/ru unknown
- 2019-03-27 AU AU2019244481A patent/AU2019244481A1/en active Pending
- 2019-03-27 MX MX2020009991A patent/MX2020009991A/es unknown
- 2019-03-27 WO PCT/IB2019/000358 patent/WO2019186276A2/en unknown
- 2019-03-27 JP JP2020551506A patent/JP2021520777A/ja active Pending
- 2019-03-27 CA CA3095443A patent/CA3095443A1/en active Pending
- 2019-03-27 KR KR1020207030584A patent/KR20200144551A/ko unknown
- 2019-03-27 CN CN201980029711.2A patent/CN112236452A/zh active Pending
-
2020
- 2020-09-24 IL IL277577A patent/IL277577A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019186276A2 (en) | 2019-10-03 |
| AU2019244481A1 (en) | 2020-10-01 |
| JP2021520777A (ja) | 2021-08-26 |
| BR112020018868A2 (pt) | 2021-01-26 |
| EP3774887A2 (en) | 2021-02-17 |
| CA3095443A1 (en) | 2019-10-03 |
| RU2020135052A (ru) | 2022-04-29 |
| IL277577A (en) | 2020-11-30 |
| WO2019186276A8 (en) | 2020-10-15 |
| KR20200144551A (ko) | 2020-12-29 |
| WO2019186276A3 (en) | 2020-02-27 |
| CN112236452A (zh) | 2021-01-15 |
| MX2020009991A (es) | 2020-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277577A (en) | Antibody-based methods for the detection and treatment of Alzheimer's disease | |
| IL254030B (en) | Use of pyridofidine to improve cognitive function and to treat Alzheimer's disease | |
| IL280315A (en) | Methods for treating and preventing Alzheimer's disease | |
| IL246999A0 (en) | Methods for treating Alzheimer's disease | |
| IL247085B (en) | Methods for treating Alzheimer's disease | |
| SG11202011296VA (en) | Compositions and methods for the treatment of parkinson's disease | |
| EP3458036A4 (en) | METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | |
| IL276896A (en) | Methods for treating Crohn's disease with a specific anti-IL23 antibody | |
| EP3377118A4 (en) | METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES | |
| EP3558340A4 (en) | METHOD FOR USE OF GM6 IN DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER | |
| IL277182A (en) | Compositions and methods for treating parkinson's disease | |
| MA45865A (fr) | Procédés de détection et de traitement d'une tumeur exprimant pt346 pdk1 | |
| EP3347486A4 (en) | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| IL288894A (en) | Methods for the assessment and treatment of Alzheimer's disease and their applications | |
| EP3398614A4 (en) | AGENT FOR THE PREVENTION AND / OR TREATMENT OF ALZHEIMER'S DISEASE | |
| ZA202101489B (en) | Compositions and methods for the treatment of parkinson's disease | |
| IL248935A0 (en) | Diagnostic testing and treatment/prevention of Alzheimer's disease | |
| PL3137097T3 (pl) | Leczenie i profilaktyka choroby Alzheimera (AD) | |
| MA41090A (fr) | Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson | |
| EP3773500A4 (en) | COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE | |
| IL281395A (en) | Treatment of early stages of Alzheimer's by replacing a small volume of plasma | |
| EP4037696A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | |
| PL3137094T3 (pl) | Leczenie i profilaktyka choroby alzheimera (ad) | |
| PL3137093T3 (pl) | Leczenie i profilaktyka choroby Alzheimera (AD) | |
| SG11202101274XA (en) | Benzimidazole compounds and use thereof for treating alzheimer's disease or huntington's disease |